There are 685 papers on clonal hematopoiesis of indeterminate potential in aging research: 10 trials and 281 observational studies in people, 50 in animals, 12 in cells, 305 reviews. The newest story, Nov 19, 2026: “Gene mutations linked to heart rhythm risk in blood cancers”.
Senolytics decrease clonal hematopoiesis of indeterminate potential in mice (genetic or pharmacological depletion of senescent non-haematopoietic cells).
“genetic or pharmacological depletion of senescent non-haematopoietic cells reduces CH burden and delays progression towards myeloid neoplasia in mice”
Reviewgenetic or pharmacological depletion of senescent non-haematopoietic cellsbone marrow
Statins were not clearly linked with clonal hematopoiesis of indeterminate potential in humans (TET2-mutant) (OR=1.05 (95% CI 0.97-1.14)).
“driven primarily by associations with DNMT3A R882-mutant (OR=0.78; 95% CI:0.66-0.92; P=0.003), but not TET2-mutant CH (OR=1.05; 95% CI:0.97-1.14; P=0.20).”
Hydroxyurea was not clearly linked with clonal hematopoiesis of indeterminate potential in humans (children with sickle cell disease) (OR 0.76; P = .44).
“CH was not associated with exposure to hydroxyurea therapy (OR, 0.76; P = .44)”
Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in humans (low-inflammatory states (low SII)) (HR 0.92, 95% CI 0.52-1.66).
“CHIP conferred no excess mortality risk in low-inflammatory states, as reflected by SII (HR, 0.92; 95% CI, 0.52-1.66)”
Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in CHIP-discordant twin pairs, controlling for familial factors (48% of affected twins died first, P = .72).
“A total of 127 twin pairs were discordant for carrying a mutation, and in 61 (48%) cases, the affected twin died first (P = .72).”
Clonal hematopoiesis of indeterminate potential increases mortality in humans (clonal hematopoiesis).
“Individuals with CH have a higher risk for hematological and non-hematological diseases, such as cardiovascular disease, and have an overall higher mortality rate.”
Clonal hematopoiesis of indeterminate potential increases mortality in humans during human aging.
“Clonally restricted hematopoiesis is associated with an increased risk of subsequent diagnosis of myeloid or lymphoid neoplasia and increased all-cause mortality.”
Clonal hematopoiesis of indeterminate potential was not clearly linked with overall survival in humans (Median OS 9.4 versus 9.6 months; HR 0.99, 95% CI 0.63–1.53; P = .95).
“overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively.”
Clonal hematopoiesis of indeterminate potential was not clearly linked with overall survival in humans (Long-term survivors of allogeneic hematopoietic cell transplantation) (94.2% vs. 92.9%; p=0.800).
“Three-year Overall survival (94.2% vs. 92.9%, p=0.800) and cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status.”
HumansLong-term survivors of allogeneic hematopoietic cell transplantation3 years after samplingn = 101
Clonal hematopoiesis of indeterminate potential is linked with lower overall survival in humans (lymphoid malignancies receiving alloBMT) (78% vs 47%, HR 3.1, 95% CI 1.4-6.8, P < .001).
“Pretransplant CH was associated with worse survival after alloBMT: 3-year overall survival (OS) was 78% (95% CI, 65-94) for patients without CH vs 47% (95% CI, 35-63) for those with CH”
Clonal hematopoiesis of indeterminate potential showed no clear effect on overall survival in humans (patients with solid tumors) (HR: 1.10, 95% CI: 0.92-1.32, p = 0.30).
“CH was not significantly associated with OS in patients with solid tumors (HR: 1.10, 95% CI: 0.92-1.32, p = 0.30).”
Journal of the Formosan Medical Association = Taiwan yi zhi·
Clonal hematopoiesis of indeterminate potential increases atherosclerosis in mice (clonal hematopoiesis in murine models).
“Murine models provide compelling evidence that a major mechanism of increased cardiovascular mortality in the context of clonal hematopoiesis is accelerated atherogenesis driven by inflammasome-mediated endothelial injury”
Clonal hematopoiesis of indeterminate potential showed no clear effect on cardiovascular disease in humans (2% to 10% VAF) (aHR 0.84, 95% CI 0.68-1.03).
“CHIP was not associated with increased risk of MACEs at 2% to 10% VAF (adjusted hazard ratio [aHR], 0.84, 95% CI, 0.68-1.03; P = .09)”
Clonal hematopoiesis of indeterminate potential was not clearly linked with second cancer in humans (Long-term survivors of allogeneic hematopoietic cell transplantation) (18.0% vs. 14.9%; p=0.410).
“cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status.”
HumansLong-term survivors of allogeneic hematopoietic cell transplantation3 years after samplingn = 101
Clonal hematopoiesis of indeterminate potential is linked with better coronary artery disease risk discrimination in humans (Added to the Framingham Risk Score) (C-statistic 0.738 to 0.786; NRI 0.142 (95% CI 0.119–0.165)).
“The C-statistic improved from 0.738 to 0.786 (p<0.001), with an NRI of 0.142 (95% CI 0.119-0.165) after adding CHIP to the Framingham Risk Score.”
HumansAdded to the Framingham Risk Score10 yearsn = 28,312
HIV was not clearly linked with clonal hematopoiesis of indeterminate potential in humans (US veterans; multivariable-adjusted analysis) (OR 0.99, 95% CI 0.77–1.29).
“HIV was not associated with the presence of CHIP in this older cohort of US veterans.”
“senescence in the bone marrow stromal microenvironment is a key contributor to the clonal growth of haematopoietic stem and progenitor cells (HSPCs) carrying CH mutations”
Inflammation increases clonal hematopoiesis of indeterminate potential.
“Chronic inflammatory stress imposes selective pressure on hematopoietic stem cells, favoring the expansion of mutation-bearing clones characteristic of clonal hematopoiesis and overt disease.”
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of cardiovascular disease in people living with HIV independent of traditional CVD risk factors.
“We observed a positive association between CH and CVD in PLWH independent of traditional CVD risk factors.”
Humansin people living with HIV independent of traditional CVD risk factors
Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans (myeloproliferative neoplasm-associated driver mutations, particularly JAK2).
“clonal hematopoiesis driven by myeloproliferative neoplasm-associated driver mutations, particularly JAK2, is associated with an increased risk of vascular and cardiac complications”
Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (US veterans with and without HIV; multivariable-adjusted analysis) (Adjusted HR 1.15, 95% CI 0.99–1.35; p = 0.073).
“baseline CHIP showed a nonsignificant trend toward higher mortality risk”
HumansUS veterans with and without HIV; multivariable-adjusted analysis17.5 years median follow-up
Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Low-CTI acute coronary syndrome cohort undergoing PCI) (Adjusted HR up to 1.94 for common CHIP mutation, 95% CI 1.09–3.45; p=0.024).
“in the low-CTI cohort, CHIP mutations—particularly common CHIP, TET2, and ASXL1 mutations—were independently associated with increased all-cause mortality”
Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Adjusted HR 1.70 for any-CHIP).
“In patients with lower SHR (<1.414), CHIP was independently associated with increased all-cause mortality (adjusted hazard ratio [HR] = 1.70 for any-CHIP).”
HumansSTEMI patients with stress hyperglycemia ratio <1.414 undergoing primary percutaneous coronary intervention
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in patients with cytopenia and chronic kidney disease (adjusted HR 3.90 (95% CI 1.41-10.83)).
“Mortality was higher in CH carriers (50.0% vs. 16.1%; p = 0.004) and remained independently associated with CH (adjusted HR 3.90; 95% CI 1.41-10.83; p = 0.009).”
Humansin patients with cytopenia and chronic kidney diseasemedian follow-up of 43.5 monthsn = 67
Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Patients hospitalized with arrhythmias; any CHIP, variant allele fraction ≥ 2%) (Adjusted HR 1.26 (1.19–1.34)).
“Both any and large CHIP were independently associated with higher mortality: adjusted hazard ratios (HRs) for all-cause mortality were 1.26 (1.19-1.34) and 1.44 (1.33-1.55), respectively;”
HumansPatients hospitalized with arrhythmias; any CHIP, variant allele fraction ≥ 2%n = 53,149
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in humans (without hematologic malignancy) (aHR 1.12, 95% CI 1.04-1.21).
“Any CHIP and large CHIP were independently associated with all-cause mortality, with multivariable-adjusted hazard ratios (aHRs) of 1.12 (95% confidence interval [CI] 1.04-1.21; P = 0.003)”
Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (critically ill ICU patients with sepsis) (OR 1.52, CI 1.09 - 2.07).
“Pre-illness CHIP was associated with increased sepsis mortality (OR 1.52, CI 1.09 - 2.07, p = 0.022, Wald test, Figure).”
Humanscritically ill ICU patients with sepsisn = 3,237
American Journal of Respiratory and Critical Care Medicine·
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in humans (sepsis in the ICU) (OR = 1.54, 95% CI 1.13 to 2.07, P = 0.005).
“Pre-illness CHIP was associated with increased sepsis mortality (OR = 1.54, 95% CI 1.13 to 2.07, P = 0.005)”
Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans.
“CHIP increases the risk of haematological malignancies and several chronic diseases (for example, cardiovascular pathologies) and contributes to persistent, low-grade inflammation or inflammageing.”
Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans (aging).
“age-related clonal hematopoiesis that originates from HSC subsets with acquired somatic mutations, and has highlighted it as a significant risk factor for hematological malignancies and cardiovascular diseases”
Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans (self-reinforcing cycle).
“inflammatory stress accelerates clonal expansion, creating a self-reinforcing cycle that contributes to atherosclerosis and other inflammation-associated complications.”
Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans.
“Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a previously unrecognized, potent, age-related, and common risk factor for atherosclerosis.”
Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in elderly patients.
“CHIP is commonly observed in elderly patients. It is characterized by an increase in blood cell clones with somatic mutations, resulting in an increased risk of hematological cancer and atherosclerotic CVD.”
Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans (specific clonal hematopoiesis-associated mutations and clonal features).
“are associated with an increased risk of progression to hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia”
Reviewspecific clonal hematopoiesis-associated mutations and clonal features
Pediatric Hematology/Oncology and Immunopathology·
Clonal hematopoiesis of indeterminate potential is associated with hematologic malignancy in humans (Over four-fold increased risk).
“While CHIP confers over a four-fold increased risk of hematologic malignancy, it has recently emerged as a key determinant of cardiometabolic health.”
Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans.
“Clonal hematopoiesis (CH) defines a premalignant state predominantly found in older persons that increases the risk of developing hematologic malignancies”
Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans (due to point mutations or structural variants) (~10-fold increased risk).
“CH due to point mutations or structural variants such as copy-number alterations is associated with an ∼10-fold increased risk of hematopoietic malignancy.”
Reviewdue to point mutations or structural variants
Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans (nested case-control analyses from two prospective cohorts) (1.9 times the risk; 95% CI, 1.4 to 2.7).
“carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers”
Humansnested case-control analyses from two prospective cohortsperipheral-blood cells
Clonal hematopoiesis of indeterminate potential raises the risk of coronary artery disease in humans.
“Clinical cohort data link CHIP to increased risk of coronary heart disease, early-onset myocardial infarction, and mortality following transcatheter aortic valve implantation.”
Clonal hematopoiesis of indeterminate potential raises the risk of coronary artery disease.
“Epidemiological studies consistently demonstrate that CH is independently associated with increased risks of coronary artery disease, heart failure, aortic stenosis, and cardiovascular mortality.”
Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans.
“uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease”
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of hematologic neoplasms in humans (biologically older CHIP carriers compared with biologically younger non-carriers) (HR 6.56, 95% CI 5.67-7.59).
“CHIP carriers who were biologically older had increased risks of hematologic neoplasms (HR 6.56, 95%CI 5.67-7.59)”
Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans.
“Clonal hematopoiesis is associated with a higher risk of developing hematological neoplasms, although most individuals never develop malignant disease.”
Clonal hematopoiesis of indeterminate potential is associated with hematologic neoplasms in patients with CHIP compared with those without CHIP (tenfold prevalence).
“The prevalence of hematopoietic neoplasms in patients with CHIP is tenfold that in those without CHIP.”
Reviewin patients with CHIP compared with those without CHIP
[Rinsho ketsueki] The Japanese journal of clinical hematology·
Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans during human aging.
“Clonally restricted hematopoiesis is associated with an increased risk of subsequent diagnosis of myeloid or lymphoid neoplasia and increased all-cause mortality.”
Inflammation is associated with clonal hematopoiesis of indeterminate potential in humans.
“highlighting links between chronic inflammation and metabolic and epigenetic changes associated with aging and in the development of clonal hematopoiesis.”
Clonal hematopoiesis of indeterminate potential is associated with inflammation in mice.
“Studies in murine models have found that some of these clonal events are involved in abnormal inflammatory and metabolic changes, altered DNA damage repair and epigenetic changes.”
Clonal hematopoiesis of indeterminate potential is associated with inflammation in humans.
“CHIP is associated with a pro-inflammatory state that has been linked to coronary artery disease, myocardial infarction, and venous thromboembolic disease”
Clonal hematopoiesis of indeterminate potential is associated with inflammation.
“clonal hematopoiesis is associated with a pro-inflammatory phenotype of hematopoietic cells and their progeny, inflammatory conditions and a poor outcome for patients with hematologic neoplasms and solid tumors.”
Age is associated with clonal hematopoiesis of indeterminate potential in humans (AML).
“Alongside age, the frequency of gene fusions defined in the World Health Organization classification decreased, while the positive rate of gene mutations, especially CH-related ones, increased.”
Clonal hematopoiesis of indeterminate potential is associated with progression-free survival in humans (Median PFS 2.4 versus 4.7 months; HR 2.50, 95% CI 0.93–6.84; P = .06).
“the presence of CH was associated with a numerically shorter PFS”
HumansBasal-like subtype of metastatic pancreatic ductal adenocarcinoma; CH-positive versus CH-negative patientsn = 23
Clonal hematopoiesis of indeterminate potential is associated with neutropenia in newly diagnosed multiple myeloma during first-line treatment (OR 4.4, P < .001).
“CH was independently associated with neutropenia during first-line treatment (odds ratio [OR]: 4.4, P < .001)”
Humansin newly diagnosed multiple myeloma during first-line treatment
The discovery cohort’s relative hazard of atrial fibrillation—an irregular heartbeat—was 1.67 for mutation carriers compared with noncarriers.The discovery cohort’s relative hazard of atrial fibrillation—an irregular heartbeat—was 1.67 for mutation carriers compared with noncarriers.
Mice followed up to one year of age showed abnormal blood formation, while repeated stem cell transplants increased mutations in blood-forming cells.Mice followed up to one year of age showed abnormal blood formation, while repeated stem cell transplants increased mutations in blood-forming cells.